241 related articles for article (PubMed ID: 33086234)
1. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
Chandiwana NC; Chersich M; Venter WDF; Akpomiemie G; Hill A; Simmons B; Lockman S; Serenata CM; Fairlie L; Moorhouse MA
AIDS; 2021 Feb; 35(2):205-211. PubMed ID: 33086234
[TBL] [Abstract][Full Text] [Related]
2. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
Hoffman RM; Brummel S; Ziemba L; Chinula L; McCarthy K; Fairlie L; Jean-Philippe P; Chakhtoura N; Johnston B; Krotje C; Nematadzira TG; Nakayiwa F; Ndyanabangi V; Hanley S; Theron G; Violari A; João E; Correa MD; Hofer CB; Navanukroh O; Aurpibul L; Nevrekar N; Zash R; Shapiro R; Stringer JSA; Currier JS; Sax P; Lockman S;
Clin Infect Dis; 2024 Jun; 78(6):1617-1628. PubMed ID: 38180851
[TBL] [Abstract][Full Text] [Related]
3. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
[TBL] [Abstract][Full Text] [Related]
4. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Jamieson L; Serenata C; Makhubele L; Sokhela S; Mashabane N; Akpomiemie G; Johnson LF; Venter WDF; Meyer-Rath G
AIDS; 2021 Dec; 35(Suppl 2):S173-S182. PubMed ID: 34848584
[TBL] [Abstract][Full Text] [Related]
5. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
7. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
Jacobson DL; Crider KS; DeMarrais P; Brummel S; Zhang M; Pfeiffer CM; Moore CA; McCarthy K; Johnston B; Mohammed T; Vhembo T; Kabugho E; Muzorah GA; Cassim H; Fairlie L; Machado ES; Ngocho JS; Shapiro RL; Serghides L; Chakhtoura N; Chinula L; Lockman S
J Infect Dis; 2024 Jun; ():. PubMed ID: 38877762
[TBL] [Abstract][Full Text] [Related]
9. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
Cindi Z; Maartens G; Bradford Y; Venter WDF; Sokhela S; Chandiwana NC; Haas DW; Sinxadi P
J Acquir Immune Defic Syndr; 2021 Jul; 87(3):1002-1009. PubMed ID: 33625064
[TBL] [Abstract][Full Text] [Related]
10. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
McCann K; Shah S; Hindley L; Hill A; Qavi A; Simmons B; Serenata C; Sokhela S; Venter WDF
AIDS; 2021 Aug; 35(10):1657-1665. PubMed ID: 33927086
[TBL] [Abstract][Full Text] [Related]
11. Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
Saborido-Alconchel A; Serna-Gallego A; Lopez-Cortes LE; Trujillo-Rodriguez M; Praena-Fernandez JM; Dominguez-Macias M; Lozano C; Muñoz-Muela E; Espinosa N; Roca-Oporto C; Sotomayor C; Herrero M; Gutierrez-Valencia A; Lopez-Cortes LF
J Antimicrob Chemother; 2023 Sep; 78(9):2354-2360. PubMed ID: 37545387
[TBL] [Abstract][Full Text] [Related]
12. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
13. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
14. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
16. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Ibrahim F; Samarawickrama A; Hamzah L; Vincent R; Gilleece Y; Waters L; Kegg S; Barbini B; Campbell L; Post FA;
HIV Med; 2021 Feb; 22(2):83-91. PubMed ID: 32985122
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
Front Immunol; 2021; 12():639378. PubMed ID: 34093527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
